革命性的患者报告结果分析用于瘤学药物开发使用人口模型
Jiawei Zhou1,2, Benyam Muluneh1,2, Quefeng Li3
1Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
概括
人口建模为在瘤学试验中分析患者报告结果 (PRO) 提供了强大的解决方案. 这种方法有效地处理数据变化和缺失值,改善治疗疗效分析.
科学领域:
- 临床试验 临床试验
- 统计建模 统计建模
- 在瘤学瘤学.
背景情况:
- 患者报告结果 (PRO) 是瘤学试验中的关键临床终点.
- 传统的统计方法在PRO数据的变化和缺失方面扎.
- 不适当的PRO分析可能导致不准确的治疗疗效结论.
研究的目的:
- 突出人口建模在瘤学PRO数据分析中的价值.
- 展示人口模型如何克服PRO数据分析中的挑战.
- 鼓励在瘤药物开发中采用人口建模.
主要方法:
- 应用个人参与者数据和人口模型.
- 纳入共变量,受试者之间的变化和测量噪声.
- 利用人口信息来准确估计缺失或稀疏数据的情况.
主要成果:
- 种群模型有效地处理PRO测量的高变量.
- 对于缺少数据的参与者,提供了准确的估计.
- 存在预测长期PRO动态的潜力.
结论:
- 人口建模可以在瘤学中彻底改变PRO数据分析.
- 这种方法可以提高对治疗对患者的影响的理解.
- 采用人口建模可以改善决策和患者护理.
相关概念视频
Analysis of Population Pharmacokinetic Data
214
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
214
Cancer Survival Analysis
319
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
319
Pharmacokinetic Models: Overview
540
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
540
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
54
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
54
Mechanistic Models: Compartment Models in Individual and Population Analysis
23
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
23
Comparing the Survival Analysis of Two or More Groups
117
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
117


